Combined medicine containing artemisinin

A technology of artemisinin and drugs, applied in the field of combined drugs, can solve problems such as insufficient absorption, less than 80% cure rate of falciparum malaria, serious drug resistance, etc., achieve the effects of reducing toxic side effects, delaying drug resistance, and improving efficacy

Active Publication Date: 2016-02-17
INST OF SCI & TECH GUANGDONG UNIV OF CHINESE MEDICINE
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the fat solubility of lumefantrine compound artemether, patients in malaria-endemic areas have insufficient absorption after taking the medicine, and the cure rate of falciparum malaria in the Cambodia-Thailand border is less than 80%
[0005] Hydroxychloroquine sulfate (HydroxychloroquineSulfate, HCQ) is a derivative of chloroquine, which belongs to 4-aminoquinoline drugs. Chloroquine is clinically limited due to severe drug resistance. Hydroxychloroquine sulfate is the drug of choice for rheumatoid arthritis. , rarely used in clinical antimalarial drugs
It has not been found that hydroxychloroquine sulfate and artemisinin can be used in combination, especially in the application of anti-malarial and treatment of autoimmune diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined medicine containing artemisinin
  • Combined medicine containing artemisinin
  • Combined medicine containing artemisinin

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0021] Experimental example 1 artemisinin and hydroxychloroquine sulfate (hereinafter referred to as AH) compound compatibility synergistic effect

[0022] 1. Materials

[0023] 1.1 Test product

[0024] 1.1.1 Artemisinin (Artemisinin, ART, hereinafter referred to as "A"): Sichuan Tongrentai Pharmaceutical Co., Ltd., batch number: 130602, purity 98.8%;

[0025] 1.1.2 Hydroxychloroquine Sulfate (Hydroxychloroquine Sulfate, HCQ, hereinafter referred to as "H"): Chongqing Kangle Pharmaceutical Co., Ltd., batch number: SQK-130403, purity 98.7%, base content 77.40%.

[0026] 1.1.3 Piperaquine phosphate: Chongqing Kangle Pharmaceutical Co., Ltd., batch number: LPK-100302-M, LPK-111003.

[0027] 1.2 Drug preparation

[0028] Use BS210S electronic balance (1 / 10,000) to weigh, add 2 to 3 drops of Tween 80 in a mortar, fully grind to make a suspension, and then dilute with distilled water to the concentration required for the experimental design. Pre-drug preparation. During use, i...

experiment example 2

[0085] Experimental example 2. Drug resistance research of AH compound prescription compatibility

[0086] The 4-day inhibitory effect of AH compound on artemisinin-resistant strains and piperaquine-resistant strains was determined, and whether AH compound had resistance to artemisinin and cross-resistance to piperaquine was evaluated.

[0087] 1. Materials

[0088] Same as Experiment 1

[0089] 2. Test method

[0090] The ED of AH compound was measured by 4-day inhibitory test method 50 / 90 , and with the ED of susceptible strains 50 / 90 Comparing and finding the resistance index I 50 / 90 , with I 50 / 90 To determine the degree of cross-resistance (I 50 / 90 = ED of resistant strain 50 / 90 / susceptible strain ED 50 / 90 ). Its standard is I 90 ≤2 is sensitive; I 90 =2~10 is mild resistance crossover; I 90 =10~100 is moderate resistance cross; I 90 >100 for severe resistance crossover.

[0091] 3. Test results

[0092] Artemisinin single drug and AH compound against ED o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a combined medicine. The combined medicine consists of artemisinin which serves as a first active ingredient, hydroxychloroquine sulfate which serves as a second active ingredient and optional pharmaceutically acceptable adjuvants. The combined medicine can be used for treating malaria more effectively, and the combined medicine can relieve drug toxicity and delay the generation of drug resistance.

Description

technical field [0001] The invention relates to a combination medicine containing artemisinin, the active ingredients of which are artemisinin and hydroxychloroquine, and the combination medicine can be used for treating malaria. Background technique [0002] Malaria is a major infectious disease in the tropics and subtropics. According to the report of the World Health Organization (WHO), the number of malaria patients in the world reaches 300-500 million people every year, and the number of deaths due to malaria is at least 600,000, of which 80% are children. Malaria is not only a serious health problem in developing countries, but also a social problem that hinders economic development and social progress. The emergence of drug-resistant Plasmodium falciparum strains and its global spread have increased the difficulty of malaria control and made the situation of global malaria control increasingly severe. Plasmodium falciparum develops resistance to drugs, which can cau...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4706A61P33/06A61K31/366
CPCY02A50/30
Inventor 宋健平袁捷邓长生郑绍琴陈颖黄博高岩徐勤周玖瑶王振华关业枝
Owner INST OF SCI & TECH GUANGDONG UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap